Lobe Sciences Ltd.

LOBE

CA53946V2066

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 19:23:18 31/05/2024 BST			5-day change	1st Jan Change
0.02 ^CAD	0.00%		+33.33%	-20.00%

01:30pm	Lobe Sciences Ltd. Announces Frederick D. Sancilio Ph.D. to Join Board of Directors	CI
05-30	Harry Jacobson to Join the Board of Directors of Lobe Sciences Ltd	CI

Lobe Sciences Ltd. Appoints Benjamin Kelmendi to Its Scientific Advisory Board

April 20, 2021 at 02:22 pm

Lobe Sciences Ltd. announced the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Latest news about Lobe Sciences Ltd.

Lobe Sciences Ltd. Announces Frederick D. Sancilio Ph.D. to Join Board of Directors	12:30pm	CI
Harry Jacobson to Join the Board of Directors of Lobe Sciences Ltd	05-30	CI
Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-29	CI
Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023	02-15	CI
Lobe Sciences Provides Update on L-130 Clinical Program	12-07	MT
Lobe Sciences Ltd. Provides Update on L-130 Clinical Program	12-07	CI
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound	12-05	MT
Lobe Sciences Appoints CFO	18/09/23	MT
Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial Officer	18/09/23	CI
Lobe Sciences Amends Terms of Altemia Share Purchase Agreement	15/09/23	MT
Lobe Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	01/08/23	CI
Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130	27/06/23	CI
Lobe Sciences Appoints Baxter Phillips as Chief Operating Officer	07/06/23	CI
Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	28/04/23	CI
Lobe Sciences Ltd. completed the acquisition of Altemia and Company, LLC from Sancilio, LLC, PBHC1, LLC and Bruce Crawford for CAD 3.8 million.	17/04/23	CI
Lobe Sciences Ltd. signed a share purchase agreement to acquire Altemia and Company, LLC for CAD 3.8 million.	17/04/23	CI
Lobe Sciences Ltd. announced that it expects to receive $0.25 million in funding	09/02/23	CI
Lobe Sciences Ltd. Reports Earnings Results for the First Quarter Ended November 30, 2022	30/01/23	CI
Lobe Sciences Ltd. Auditor Raises 'Going Concern' Doubt	21/12/22	CI
Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2022	21/12/22	CI
Lobe Sciences Ltd. Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130	30/11/22	CI
Lobe Sciences Ltd. Appoints Baxter F. Phillips III to the Board of Directors	05/10/22	CI
Lobe Sciences Ltd. Announces Resignation of Jonathan Gilbert of Board Chairman	03/10/22	CI
Lobe Sciences Ltd. Announces the Expansion of Its Patent Portfolio with International Filings	03/10/22	CI
Lobe Sciences Ltd. announced that it has received CAD 1.41314 million in funding	07/09/22	CI

Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.

Sector

Pharmaceuticals

Calendar

27/06/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
LOBE SCIENCES LTD.	-20.00%	2.51M
DONG-E-E-JIAO CO.,LTD.	+37.29%	6.09B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-21.28%	4.14B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+4.52%	3.23B
TASLY PHARMACEUTICAL GROUP CO., LTD	-18.16%	2.83B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-7.70%	2.39B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.50%	1.9B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.05%	1.57B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-15.56%	1.55B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.62%	1.5B

Alternative Medicine